Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Industry Poised for Rapid Growth, Forecast to Touch $3.46 Billion by 2030 at 9.3% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market from 2026–2035 with trusted insights from The Business Research Company
What upper market value could the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market reach by 2030 starting from 2026 levels?
The market for chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing has experienced significant expansion recently. This market is projected to expand from $2.19 billion in 2025 to $2.43 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 10.9%. Historically, this growth has been driven by factors such as increased screening among sexually active individuals, the development of laboratory-based testing infrastructure, the embrace of NAAT and PCR diagnostic methods, heightened understanding of co-infection dangers, and the proliferation of diagnostic laboratories.
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size is projected to experience significant growth in the coming years, reaching $3.47 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9.3%. This projected growth can be attributed to several factors during the forecast period, including increasing investments in decentralized testing, the rising adoption of home-based diagnostics, the expansion of automated laboratory platforms, a growing emphasis on early STI detection, and an increasing demand for integrated CT/NG testing solutions. Major trends anticipated in the forecast period encompass the increasing adoption of multiplex STI testing panels, a rising demand for rapid point-of-care testing, the growing use of self-testing kits, the expansion of high-sensitivity molecular assays, and enhanced integration of laboratory automation.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp
Which Drivers Are Influencing Long-Term Growth In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The escalating prevalence of sexually transmitted infections (STIs) is projected to boost the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the future. STIs are defined as illnesses caused by bacterial, viral, or parasitic infections transferable through sexual contact. The rise in STI rates can be attributed to several factors, including inadequate comprehensive sex education, increased engagement in sexual activity, social stigma, and various barriers. Chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing plays a crucial role in the detection and management of sexually transmitted infections, allowing for early diagnosis, appropriate treatment, and the prevention of further spread. For instance, in October 2025, the Minority HIV/AIDS Fund (MHAF), a US-based government agency, reported that an estimated 39.9 million individuals globally were living with HIV in 2023, which included 38.6 million adults and 1.4 million children, representing a rise compared to previous years. This demonstrates the increasing number of sexually transmitted infections, which is actively driving the growth of the CTNG testing market.
How Is The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Divided Into Segments?
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market covered in this report is segmented –
1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users
Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT), Polymerase Chain Reaction (PCR) Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Culture Tests, Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT), Lateral Flow Assays, Immunochromatographic Tests, Self-Testing Kits, Loop-Mediated Isothermal Amplification (LAMP), Microfluidics-Based Tests
What Trends Are Expected To Impact The Competitive Landscape Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Major companies within the chlamydia market are concentrating on creating advanced solutions, including the expansion of Point-of-Care Molecular Diagnostics, to facilitate quicker, more precise onsite detection and enhance prompt treatment results. This expansion signifies the increased implementation of rapid molecular tests performed at the point of care, enabling immediate identification of infections like chlamydia without the need for central lab processing. For example, in January 2025, the Swiss healthcare firm F. Hoffmann-La Roche AG secured FDA 510(k) clearance and a CLIA waiver for its cobas® liat molecular tests, developed for diagnosing sexually transmitted infections (STIs) directly at the point of care. These specific tests incorporate multiplex assay panels capable of identifying and distinguishing several STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a singular patient sample, providing results within 20 minutes or less.
Which Key Players Are Driving Competition In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Major companies operating in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc, PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc, Meridian Bioscience Inc, Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd, Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd, NG Biotech
Access The Complete Report For Deeper Market Insights:
How Does The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Perform Across Major Global Regions?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2025. The regions covered in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=14667&type=smp
Browse Through More Reports Similar to the Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market 2026, By The Business Research Company
Chlamydia Infection Diagnostics And Therapeutics Market Report 2026
Chlamydia Infection Diagnostics Market Report 2026
Std Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/std-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
